{"prompt": "['Boehringer Ingelheim', '16 Dec 2019', 'BI Trial No.: 1199-0324', 'c19558808-06', 'Clinical Trial Protocol', 'Page 4 of 103', 'Proprietary confidential information \u00a9 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies', 'Absolute change from baseline of FVC and FVC %', 'predicted', 'Relative change from baseline of FVC and FVC %', 'predicted', 'Absolute categorical change of FVC % predicted up', 'to 12 and 24 weeks: decrease by >5%, increase by', '>5%, and change within <5', 'Absolute categorical change of FVC% predicted up', 'to 12 and 24 weeks: decrease by >10, increase by', '10, and change within 10', 'Change from baseline in daily accelerometer activity from', 'baseline at 12 and 24 weeks', 'Safety criteria:', 'Vital signs, physical examination, weight', 'Clinical laboratory tests (haematology, clinical chemistry,', 'and urinalysis)', 'Reporting of adverse events', '12 lead electrocardiogram', 'Statistical methods:', 'The primary (6MWD at 12 weeks) will be analysed using the', 'Analysis of Covariance model including intervention as a fixed', 'categorical covariate and baseline 6MWD as continuous covariate', '6MWD will be analysed on the original scale.', 'all other', 'assessments will be analysed using original scales.', '001-MCS-40-106-RD-03 (14.0) / Saved on: 17 October 2016']['Boehringer Ingelheim', '16 Dec 2019', 'BI Trial No.: 1199-0324', 'c19558808-06', 'Clinical Trial Protocol', 'Page 5 of 103', 'Proprietary confidential information C 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies', 'For secondary', 'endpoints, 12-week endpoints will', 'be analysed using similar ANCOVA methodology as the primary', 'endpoint. The 24-week endpoints will be analyzed using a mixed', 'model with repeated measures.', 'Descriptive statistics will be shown for all efficacy and safety', 'endpoints.', '001-MCS-40-106-RD-03 (14.0) / Saved on: 17 October 2016']['Boehringer Ingelheim', '16 Dec 2019', 'BI Trial No.: 1199-0324', 'c19558808-06', 'Clinical Trial Protocol', 'Page 6 of 103', 'Proprietary confidential information \u00a9 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies', 'FLOW CHART', 'Screening', 'Interventional Period', 'Treatment', 'Visit', '0', '1', '2', '3', '4', '5', '6', '7 (EOT)', 'Weeks of treatment', '-2', '-1', '0', '3', '6', '12', '18', '246', 'Day', 'At least 7', '7d', '1', '22', '43', '85', '127', '169', 'days', 'before V2', 'Time window', 'before', '+3', '+3', '+3', '+3', '7', 'visit 1', 'Informed consent', 'X*', 'Demographics/baseline conditions', 'X', 'Medical history', 'X', 'In-/exclusion criteria', 'X', 'X', 'X', 'Physical examination?, vital signs', 'X', 'X', 'X', 'X', 'Laboratory test', 'X', 'X', 'Pregnancy test', 'X', 'X', 'Spirometry (FVC)', 'X', 'X', 'X', 'X', 'SpO2 (peripheral capillary oxygen saturation)', 'DLco', 'X', 'X', 'HRCT sent for outcomes review\u00b9', 'x\u00b9', '12-lead electrocardiogram (ECG)', 'X', 'X', '(Practice) Six-minute walk test', 'X', 'Six minute walk test', 'X', 'X', 'X', 'Instruct Patient on Activity Monitoring and', 'X', 'X', 'X', 'PROactive tool (eDiary)2', 'Activity Monitoring (Dynaport)', 'X', 'X', 'X', 'SGRQ, KBILD, UCSD SOBQ', 'X', 'X', 'PROactive Tool', '2,3', 'X', 'X', 'X', 'Randomisation', 'Schedule pulmonary rehab days for assigned', '6', 'patients', 'Record pulmonary rehab', 'IRT', 'X', 'Adverse events, concomitant treatments', 'X', 'X', 'X', 'X', 'X', 'Conclude subject participation', 'X', '*', 'Informed consent needs to be signed before any procedure related to the study, all AEs and Concomitant Treatments', 'occurring after the Informed consent have to be recorded.', '1', 'HRCT will be acceptable if done within 24 months, if not available patient will be sent for HRCT between Visit 1 and 2,', 'or within 7 days of completing Visit 2.', '2', 'Patients will wear the physical activity monitor and complete the eDiary (PROactive Tool) 24 hours every day for 1 week', 'prior to Visits 1, 2, 5 and 7. Devices will be dispensed in clinic at Visits 0 and 1, and will be shipped to patient or picked', 'up from clinic at least 1 week prior to Visits 5 and 7.', '3', 'I', 'exercise testing center. The incremental and practice tests can both be done at Visit 1.', '5', 'Access IRT to terminate if screen fail at Visit 1 or between Visit 0 and Visit 1.', '001-MCS-40-106-RD-03 (14.0) / Saved on: 17 October 2016']\n\n###\n\n", "completion": "END"}